« Back to Record
Citation APA

Carey, L. L., Loirat, D., Punie, K., Bardia, A., Diéras, V., Dalenc, F., Diamond, J. J., Fontaine, C., Wang, G., Rugo, H. H., Hurvitz, S., Kalinsky, K., O'Shaughnessy, J., Loibl, S., Gianni, L., Piccart-Gebhart, M., Zhu, Y., Delaney, R., Phan, S., & Cortes, J. (2022). Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis. NPJ breast cancer, 8(1), 72. doi:10.1038/s41523-022-00439-5


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/350453

Carey, L. L., Loirat, D., Punie, K., Bardia, A., Diéras, V., Dalenc, F., Diamond, J. J., Fontaine, C., Wang, G., Rugo, H. H., Hurvitz, S., Kalinsky, K., O'Shaughnessy, J., Loibl, S., Gianni, L., Piccart-Gebhart, M., Zhu, Y., Delaney, R., Phan, S., & Cortes, J. (2022). Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis. NPJ breast cancer, 8(1), 72. doi:10.1038/s41523-022-00439-5